Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
181-200 of 331 trials

Norfloxacin for Portal Hypertension in Decompensated Cirrhosis

We are studying whether norfloxacin can lower portal hypertension in patients with decompensated cirrhosis. The trial also looks at its effects on liver-related complications and overall patient well-being.

Portal HypertensionDecompensated Cirrhosis3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesGastroenterologyHepatology

Acute Bacterial Prostatitis: Fosfomycin vs. Cefixime

We are comparing two oral antibiotics to see which one better resolves urinary symptoms in men with acute bacterial prostatitis. The study will also look at any side effects and the effectiveness of the treatments over time.

Acute Bacterial Prostatitis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesUrology

Peritonitis Treatment: Pentaglobin® Study

We are investigating whether Pentaglobin® can improve organ function and reduce the risk of death in patients recovering from peritonitis. This study looks at changes in health over time after infection control.

SepsisSeptic ShockSeptic Peritonitis3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Idiopathic Inflammatory Myopathies: Upadacitinib Study

We are testing whether Upadacitinib can help patients with idiopathic inflammatory myopathies maintain stable disease after stopping IVIG treatment. The study compares its effects to a placebo over 16 weeks.

PolymyositisDermatomyositisAntisynthetase Syndrome3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesDermatologyRheumatology

Intrahepatic Cholangiocarcinoma: PUMP IV Trial

We are studying a new chemotherapy method to help prevent liver cancer from coming back after surgery. This trial will also look at side effects and how it affects patients' quality of life.

Intrahepatic Cholangiocarcinoma3-6 monthsEfficacy phase (II)6-10 visitsCost ReimbursementGastroenterologyHepatologyOncology

Angiosarcoma and Undifferentiated Pleomorphic Sarcoma: Propranolol and Pembrolizumab Study

We are studying the effects of a new treatment combining propranolol and pembrolizumab for patients with advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. The goal is to see if this combination improves survival and quality of life.

Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Esophageal Cancer: Trastuzumab and Pertuzumab Study

We are studying if adding trastuzumab and pertuzumab to standard treatment helps improve survival for patients with HER2 positive esophageal adenocarcinoma. This trial involves patients whose cancer can be surgically removed.

HER2 Positive Esophageal Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Alzheimer's Agitation: Masupirdine Study

We are investigating whether masupirdine can help reduce agitation symptoms in people with Alzheimer's. The study will compare its effects to a placebo over 12 weeks.

Alzheimer's Disease3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Chronic Rhinosinusitis with Nasal Polyps: Tezepelumab Study

We are investigating how tezepelumab affects symptoms in adults with chronic rhinosinusitis and nasal polyps. The study looks at changes in nasal congestion, sense of smell, and overall quality of life.

Chronic Rhinosinusitis with Nasal Polyps3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

HIV Treatment: IMC-M113V Study

We are evaluating a new treatment, IMC-M113V, for people with chronic HIV infection who are already on medication. The study will help us understand its safety and how it affects the immune system.

Chronic HIV Infection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Heart Failure and Kidney Disease: SENEKA Study

We are exploring a new treatment strategy for elderly patients with heart failure and chronic kidney disease to see if it helps manage potassium levels better. This study compares a potassium binder with standard medications to improve patient outcomes.

Chronic Heart Failure and Non-Dialysis Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology

Papillary Renal Cell Carcinoma: Axitinib with or without Pembrolizumab

We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.

Metastatic Renal Cell CarcinomaLocally Advanced or Metastatic Papillary Cell Carcinoma3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Early Stage Arthritis: Baricitinib Study

We are studying the effects of baricitinib on joint inflammation in people with early stage arthritis. The trial will also look at safety and potential indicators of disease progression.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Standard MedicinesRheumatology

Heart Failure: Vericiguat Study

We are studying the effects of vericiguat in patients with heart failure and reduced ejection fraction. The goal is to see if it can lower heart failure markers compared to a placebo.

Heart Failure with Reduced Ejection Fraction (HFrEF)3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Yellow Fever Vaccination: Comparing Injection Methods

We are studying how different ways of giving the yellow fever vaccine affect the immune response in participants. This trial aims to find out which method may provide better protection and safety.

Yellow Fever3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Severe Functional Disorders: Duloxetine and Patient Education

We are studying the effects of patient education and duloxetine on individuals with severe functional disorders. This research aims to explore how these factors may influence symptoms and inflammation.

Functional Somatic Disorder3-6 monthsMonitoring phase (IV)Investigational MedicinesInternal MedicineNeurologyPsychiatry

Actinic Keratosis: 5% Potassium Hydroxide Solution

We are studying whether a 5% potassium hydroxide solution is more effective than a placebo for treating mild to moderate actinic keratosis. The trial also looks at the safety of this treatment.

Actinic Keratosis3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

Pulmonary Hypertension: TX000045 Treatment Study

We are testing a new medication, TX000045, for patients with pulmonary hypertension due to heart failure. The goal is to see if it improves heart function and is safe for use.

Pulmonary Hypertension3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Mixed Dyslipidaemia: Rosuvastatin and Fenofibrate Study

We are comparing two medication combinations to see which one better lowers bad cholesterol in patients with mixed dyslipidaemia at high risk for heart disease. This study will help us understand their effectiveness and safety.

Dyslipidemia3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

Cystectomy: Targeted Antibiotic Prophylaxis Study

We are testing whether a personalized antibiotic treatment can help reduce hospital readmissions due to infections after bladder surgery. This study compares it to the standard antibiotic approach used during stent removal.

Bacterial Infection3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesUrology